NCT01242527已完成2 期
Efficacy and Safety of Epanova® (Omefas) in Severe Hypertriglyceridemia
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- AstraZeneca
- 入组人数
- 399
- 主要终点
- Fasting Serum Triglycerides
研究概览
简要总结
The primary objective of the study is to determine the efficacy of Epanova (omefas) compared to placebo in lowering serum triglycerides in subjects with severe hypertriglyceridemia.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men or women, >=18 years of age.
- •Very high serum TG values in the range >=500 mg/dL and <2000 mg/dL (>=5.65 mmol/L and <22.60 mmol/L)
排除标准
- •Allergy or intolerance to omega-3 fatty acids, omega-3-acid ethyl esters, or fish.
- •Known lipoprotein lipase impairment or deficiency or apolipoprotein C-II deficiency or familial dysbetalipoproteinemia.
- •Unable to discontinue use of omega-3 drugs/supplements.
- •Unable to discontinue use of bile acid sequestrants, fibrates or niacin (other than niacin-containing vitamins <200 mg), or any supplement used to alter lipid metabolism.
- •Women who are pregnant, lactating, or planning to become pregnant. Women of childbearing potential who are not using acceptable contraceptive methods.
- •Use of tamoxifen, estrogens or progestins that has not been stable for >4 weeks prior to Visit
- •Use of oral or injected corticosteroids or anabolic steroids.
- •History of pancreatitis.
- •History of symptomatic gallstone disease, unless treated with cholecystectomy.
- •Uncontrolled diabetes.
- •Uncontrolled hypothyroidism or thyroid stimulating hormone (TSH).
- •History of cancer (other than basal cell carcinoma) in the past 2 years.
- •Cardiovascular event (i.e., myocardial infarction, acute coronary syndrome, new onset angina, stroke, transient ischemic attack, unstable congestive heart failure requiring a change in treatment) or revascularization procedure within six months prior to Visit
- •Use of anticoagulants (e.g. warfarin [Coumadin®], coumarin, heparin, enoxaparin, clopidogrel).
- •Presence of an aortic aneurysm or resection of an aortic aneurysm within six months prior to Visit
- •Recent history (within six months prior to Visit 1) or current significant nephrotic syndrome, pulmonary, hepatic, biliary, gastrointestinal or immunologic disease.
- •Poorly controlled hypertension.
- •Any of the following laboratory criteria: serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST), glucose, glomerular filtration rate (GFR), platelet count,or hemoglobin outside of study range.
- •Recent history (past 12 months) of drug abuse or alcohol abuse.
- •Exposure to any investigational product, within 4 weeks prior to Visit
- •Presence of any other condition the Investigator believes would interfere with the subject's ability to provide informed consent, comply with study instructions, or which might confound the interpretation of the study results or put the subject at undue risk
研究组 & 干预措施
Epanova 2 g
Experimental
干预措施: omefas (Drug)
Epanova 3 g
Experimental
干预措施: omefas (Drug)
Epanova 4 g
Experimental
干预措施: omefas (Drug)
placebo
Placebo Comparator
干预措施: placebo (Drug)
结局指标
主要结局
Fasting Serum Triglycerides
时间窗: 12 weeks
The primary endpoints are the differences in mean percent changes from baseline to end-of-treatment in triglycerides between placebo and the 2g/day, 3g/day and 4g/day Epanova groups
次要结局
未报告次要终点
研究者
相似试验
已完成
1 期
Interaction of Epanova on Warfarin Pharmacokinetic and Anticoagulant Activity and Comparison of the Effects of Epanova and Lovaza on Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA) After Low-fat MealsHypertriglyceridemiaNCT01431690AstraZeneca52
已完成
1 期
The Effect of Multiple Doses of Epanova® on the Multiple-Dose Pharmacokinetics of Simvastatin in Healthy Normal SubjectsHypertriglyceridemiaNCT01486433AstraZeneca52
已完成
3 期
An Efficacy and Safety Study of Omega-3 Free Fatty Acids (Epanova™) for the Maintenance of Symptomatic Remission in Subjects With Crohn's DiseaseCrohn's DiseaseNCT00074542Tillotts Pharma AG364
终止
1 期
A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 2)Advanced Solid TumorsNCT00550017Bristol-Myers Squibb39
终止
1 期
A Phase 1/2 Study of Epofolate (BMS-753493) in Subjects With Advanced Cancer (Schedule 1)Advanced Solid TumorsNCT00546247Bristol-Myers Squibb26